Clinical Trials
6 trialsNCT02484404 2026-05-06
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT04456699 2024-10-29
LYNK-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04166435 2023-09-06
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Yale University
Phase 2 Completed
NCT00535353 2023-08-04
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
Canadian Cancer Trials Group
Phase 1 Completed
NCT05201612 2023-02-24
PEMBROLA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Unknown
NCT00912743 2016-11-09
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
AstraZeneca
Phase 2 Completed